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Abstract: The complement system is an important part of innate immunity; however, as with 
other parts of the immune system, the complement system can become pathologically activated 
and create or worsen disease. Anticomplement reagents have been studied for several years, but 
only recently have they emerged as a viable therapeutic tool. Here, we describe the role of the 
complement system in a wide array of diseases, as well as the use of anticomplement therapy 
as treatment for these diseases in animal models and in human clinical trials. Speciﬁ  cally, we 
will discuss the role of anticomplement therapy in paroxysmal nocturnal hemoglobinuria, glo-
merulonephritis, and heart disease, including coronary artery disease, myocardial infarction, 
and coronary revascularization procedures such as percutaneous coronary angioplasty and 
coronary artery bypass graft surgery.
Keywords: complement, paroxysmal nocturnal hemoglobinuria, glomerulonephritis, myocardial 
infarction, cardiopulmonary bypass
Introduction
The complement system, as a part of innate immunity, carries out a wide array 
of functions, including protection against foreign organisms, removal of immune 
complexes from the circulation, and clean-up of cellular debris which accumulates 
over time. The complement system also plays a signiﬁ  cant role in the initiation and 
propagation of the inﬂ  ammatory response. Besides its beneﬁ  cial effect, though, the 
complement system can also play a detrimental role in many pathologic conditions.
The complement system comprises several plasma and cell surface proteins, 
including complement regulatory proteins. When these complement regulatory 
proteins do not function properly, the complement system can become improperly 
activated and cause tissue damage. Over the last several years, a signiﬁ  cant amount 
of work has been done to study complement activation in certain disease states 
and whether there is any role for complement inhibition in the treatment of these 
diseases. In this paper, we will review the function and regulation of the complement 
system, give a brief description of various complement inhibitors, and discuss the 
recent use of anticomplement therapeutics in speciﬁ  c diseases, namely paroxysmal 
nocturnal hemoglobinuria, glomerulonephritis, and heart disease, including coronary 
artery disease, myocardial infarction, and cardiac surgery requiring the use of 
cardiopulmonary bypass.
Overview of the complement system
Activation of the complement system
The complement system comprises more than 30 plasma proteins, most of which are 
synthesized by the liver. The complement system acts through three major pathways, 
the classical pathway, activated by antigen-antibody complexes; the alternative 
pathway, activated spontaneously by attachment of C3b to a particular surface; and 
the lectin pathway, activated by the binding of mannan-binding lectins to carbohydrate 
ligands on the surface of pathogens (Figure 1) (Janeway et al 1999; Qin and Gao 2006; Biologics: Targets & Therapy 2008:2(4) 672
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Cummings et al 2007; Oksjoki et al 2007). The central 
convergence point of all three pathways is the formation of 
a C3 convertase on the surface of a particular cell. With the 
formation of a functioning C3 convertase, complement is 
able to carry out its effector functions (Figure 2).
In the classical pathway, C1q, one of the subunits of C1, 
ﬁ  rst binds to the Fc domains of antibodies attached to their 
antigen. Another subunit of C1, C1r, cleaves and activates 
the third subunit of C1, C1s. Activated C1s cleaves C4 and 
C2 to form C4b and C2b, respectively, which then combine 
to form the C3 convertase of the classical complement 
pathway (Figure 1). Similarly, in the lectin pathway, cleavage 
of C4 and C2 allow formation of the C3 convertase. In the 
alternative pathway, C3 is spontaneously cleaved to C3a 
and C3b. C3b covalently binds to cell surfaces and with the 
help of factor B (FB) and factor D (FD) can form the C3bBb 
complex, which is the alternative pathway’s C3 convertase 
(Figure 1).
The function of the C3 convertase in all three pathways 
is to further cleave C3, producing C3a, one of the two major 
anaphylatoxins of the complement system, and C3b, a potent 
opsonin. Binding of several C3b molecules to cells and 
other debris marks them for phagocytosis by macrophages. 
Propagation of complement activation by the C3 convertase 
results in the generation of a C5 convertase on cell surfaces. 
The function of the C5 convertase is to cleave C5 to C5a and 
C5b. C5a is the other anaphylatoxin and is much more potent 
than C3a. As anaphylatoxins, C3a and C5a are able to recruit 
neutrophils to areas of inﬂ  ammation and damage. C5b is 
subsequently able to bind to C6, C7, C8, and C9 to form the 
membrane attack complex (MAC or C5b-9 complex). The 
C5b-9 complex is able to disrupt the phospholipid bilayer of 
the cell membrane, leading to loss of cellular homeostasis 
and eventual cell death (Figure 2).
Thus, the three main functions of the complement system 
are opsonization of pathogens or other molecules, which 
targets them for eventual destruction, augmentation of 
inﬂ  ammation by the recruitment of inﬂ  ammatory cells via 
the anaphylatoxins C3a and C5a, and direct killing of cells 
by the formation of MACs (Figure 2).
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Figure 1 Activation pathways of the complement system and complement regulatory proteins. Three pathways of activation of the complement system (the classical, 
alternative and lectin pathways), their convergence on a common pathway, and the components of each pathway are depicted. The effect of different complement regulatory 
proteins is shown as dashed lines.
Abbreviations: MBL, mannan-binding lectin; MASP1/2, MBL-associated serine protease 1 and 2; C1INH, C1 inhibitor; C4bBP, C4b binding protein, DAF, decay accelerating 
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Regulation of the complement system
Because the complement system has such a potent ability to 
cause cellular damage, it is extensively regulated both in the 
ﬂ  uid phase and on cell surfaces. We will brieﬂ  y describe the 
major complement regulatory proteins.
In the classical pathway, one of the main complement 
regulatory proteins is C1 inhibitor (C1-INH), which binds to 
the C1r:C1s complex and causes it to dissociate from C1q, 
thus preventing activation of the complement system. The 
function of the other major complement regulatory proteins 
can be categorized under two major activities: (1) breaking 
up the C3 convertase, termed decay-accelerating activity and 
(2) cleavage of either C3b or C4b to their inactive forms, iC3b 
and iC4b, respectively, termed membrane co-factor activity. 
Proteins with decay-accelerating activity which regulate 
the classical pathway include C4-binding protein (C4bp), 
complement receptor 1 (CR1), and decay-accelerating factor 
(DAF) or CD55. Proteins with decay-accelerating activity 
which regulate the alternative pathway include CR1, factor 
H (FH), and DAF (Figure 1).
All membrane co-factor activity relies on the function 
of a serine protease known as factor I (FI). Factor I, in 
turn, requires at least one of several potential co-factors to 
degrade C3b and C4b. For the classical pathway, proteins 
with membrane co-factor activity include C4bp, CR1, and 
membrane co-factor protein (MCP), while those for the 
alternative pathway are CR1, FH, and MCP.
Another important regulatory protein is CD59, also 
known as protectin. CD59 prevents formation of the C5b-9 
complex (MAC) on cell surfaces and is highly expressed on 
cell membranes throughout the body.
Development of complement 
inhibitors
The ﬁ  rst complement inhibitor described in the scientiﬁ  c 
literature was cobra venom factor (CVF). The anticomplement 
activity of cobra venom was described by Flexner and 
Noguchi in 1903 (Flexner and Noguchi 1903). It was not 
until the late 1960’s and early 1970’s that the component 
of cobra venom responsible for its anticomplement activity 
was recognized (Gewurz et al 1967; Maillard and Zarco 
1968; Cochrane et al 1970; Phillips 1970; Muller-Eberhard 
and Fjellstrom 1971). CVF binds to mammalian FB in 
plasma and after cleavage of FB by FD, a stable, soluble C3 
convertase is produced, the CVF-Bb complex (Cooper 1973). 
The CVF-Bb complex consumes C3 in the plasma very 
efﬁ  ciently; in fact, a single injection of CVF can completely 
eliminate complement activity for 24–72 hours in certain 
animal models (Morgan and Harris 2003).
One of the ﬁ  rst synthetic molecules to be developed 
for anticomplement therapy was nafamastat mesilate, also 
known as FUT-175. This molecule inhibits C1r, C1s, C3 
convertase, C5 convertase, and FD (Fujii and Hitomi 1981; 
Inagi et al 1991). Nafamastat mesilate is not entirely 
complement-speciﬁ  c, however, and can inhibit several other 
plasma proteases (Hitomi and Fujii 1982).
Using phage display random peptide libraries, several com-
plement inhibitors have been discovered. Compstatin, which 
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is composed of only 13 amino acid residues, binds to C3 
and inhibits its cleavage by C3 convertase (Sahu et al 1996). 
Molecules blocking C1q in vitro have also been obtained 
from random peptide libraries (Roos et al 2001).
Interestingly, heparin has long been known to possess 
anticomplement properties (Weiler et al 1978). Its effects 
include binding to and subsequent inactivation of C1, 
inhibition of MAC assembly, and blockage of the formation 
of C3 convertase (Baker et al 1975; Hughes-Jones and 
Gardner 1978; Almeda et al 1983; Weiler 1983).
Another category of complement inhibitors is recombinant 
proteins that are engineered using genes encoding membrane 
complement regulatory proteins. These recombinant proteins 
have been genetically modiﬁ  ed to make them soluble so that 
they inhibit complement activation in the ﬂ  uid phase. One of 
the ﬁ  rst recombinant complement inhibitors was soluble CR1 
(sCR1), also known as TP10. Weisman et al developed this 
molecule, which comprises the entire extracellular domain 
of CR1, and showed that it inhibited formation of C3 and C5 
convertases in vivo (Weisman et al 1990a, 1990b). Soluble 
recombinant MCP and DAF have also been developed and 
have been shown to inhibit complement both in vitro and in 
vivo (Moran et al 1992; Christiansen et al 1996). A hybrid 
molecule named complement activation blocker-2 (CAB-2) 
was designed by fusing the functional domains of MCP and 
DAF (Higgins et al 1997). In vitro CAB-2 was shown to 
inhibit complement activation (Kroshus et al 2000).
Another logical approach to inhibition of the complement 
system is to use a blocking antibody against one of the 
many interacting complement proteins. N19-8, the ﬁ  rst 
anticomplement monoclonal blocking antibody developed, 
was shown to block C5 cleavage in vitro (Wurzner et al 
1991). Subsequently, a second antibody to human C5, termed 
h5G1.1, was developed (Kroshus et al 1995). This molecule 
was modiﬁ  ed to have only single-chain Fv fragments but still 
retain full antiC5 activity (Thomas et al 1996).
Using recombinant DNA technologies, investigators 
became able to combine complement-binding antibodies to 
inhibitory domains of complement regulatory proteins. There 
are two different ways in which these hybrid molecules have 
been designed. One way is to use the Fab portion (the antigen-
binding fraction) of the antibody to direct the molecule 
toward a particular cell membrane component, while the Fc 
portion (the constant fraction) is the soluble complement 
regulator itself. Two examples of hybrid molecules created 
in this way are antidansyl Fab arms fused with either CD59 
or DAF (Zhang et al 1999, 2001). Both fusion proteins were 
able to avidly bind to dansyl-labeled Chinese hamster ovary 
cells. Another way to fuse antibody fragments to soluble 
complement inhibitors is to use the complement inhibitors 
themselves as the Fab arms of the molecule and to use the 
normal Fc portion of the antibody to keep the molecules 
in the circulation longer (Pugsley 2001). One downside to 
this approach is reduced activity of the hybrid molecule as 
compared to a pure soluble complement inhibitor, perhaps 
due to a steric hindrance (Harris et al 2002).
Complement inhibition as therapy 
for disease
The possibility of complement inhibition as therapy 
for various disease states has been studied in organ 
transplantation, ischemia-reperfusion injury, coronary artery 
disease, myocardial infarction, stroke, infection, cancer, 
immunosuppression, paroxysmal nocturnal hematuria, 
glomerulonephritis, rheumatoid arthritis, and acute 
respiratory distress syndrome, and has also been used in 
the coating of extracorporeal circuits in cardiopulmonary 
bypass and dialysis (Table 1). Any possible beneﬁ  t from 
inhibiting the complement system should be balanced with 
potential side effects, such as an increased susceptibility to 
infection with encapsulated bacteria, Neisseria meningitidis 
in particular, and autoimmune diseases caused by decreased 
clearance of immune complexes. In this review, we will 
focus on anticomplement therapy in paroxysmal nocturnal 
hemoglobinuria, glomerulonephritis, coronary artery 
disease, myocardial infarction, and cardiac surgery requiring 
cardiopulmonary bypass.
Paroxysmal nocturnal hemoglobinuria
Overview and pathophysiology
Paroxysmal nocturnal hemoglobinuria (PNH) is a 
clonal disorder due to an acquired somatic mutation in 
the X-linked phosphatidylinositol glycan complementation 
class A (PIG-A) gene, which leads to a partial or com-
plete deﬁ  ciency of all proteins which are usually linked 
to the cell membrane via a glycosyl phosphatidylinositol 
(GPI) anchor (Takeda et al 1993; Bessler et al 1994). 
DAF and CD59, complement regulatory proteins, are two 
GPI-anchored molecules; therefore, PNH cells have a deﬁ  -
ciency of DAF and/or CD59 on their cell membrane and 
are more susceptible to destruction by complement. The 
proportion of normal stem cells and PNH stem cells in any 
one patient can vary, but PNH cells usually constitute the 
majority of hematopoietic cells (Richards et al 2007). The 
clinical features of PNH include intravascular hemolysis, 
bone marrow failure, and a predisposition to thrombosis Biologics: Targets & Therapy 2008:2(4) 675
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(Hillmen et al 1995; Socie et al 1996). Patients usually 
have acute severe hemolytic episodes with a chronic mild 
hemolysis in the background (Hill et al 2007). Despite the 
extensive hemolysis, the major cause of morbidity and 
mortality in PNH is venous thrombosis, which occurs in 
about 50% of patients and is responsible for one-third of 
deaths in PNH (Hillmen et al 1995; Socie et al 1996). The 
cause of PNH patients’ predilection to thrombosis is currently 
unknown (Hill et al 2007). While venous thrombosis is the 
major cause of morbidity and mortality in PNH, many patients 
also develop pancytopenia due to aplastic anemia (Hill et al 
2007). The median survival of patients with PNH from the 
time of diagnosis is about 10–15 years. However, approxi-
mately 15% of patients experience spontaneous regression of 
PNH with no residual sequelae (Hillmen et al 1995).
Therapy
Standard therapy for PNH includes supportive care with red 
blood cell (RBC) transfusions and treatment of thrombotic 
complications (Hill et al 2007). The only deﬁ  nitive cure for 
PNH currently is allogeneic bone marrow transplantation 
(BMT), with indications for this similar to the indications 
for BMT in aplastic anemia.
In the past several years, studies have been conducted on 
the humanized monoclonal antibody eculizumab (Alexion 
Pharmaceuticals, Soliris, Cheshire, Connecticut, USA), 
which is directed against human C5 (Thomas et al 1996). In 
2004, a pilot study using 11 patients with PNH was conducted 
in which the patients received infusions of eculizumab over 
a period of 12 weeks (Hillmen et al 2004). In this small 
study, mean lactate dehydrogenase (LDH) levels decreased 
signiﬁ  cantly over the course of the study; the percentage of 
PNH erythrocytes increased signiﬁ  cantly; transfusion rates 
declined; and the occurrence of hemoglobinuria subsided 
dramatically. All of the patients from this study chose to 
participate in a 52-week extension of the study, in which they 
received eculizumab infusions every 12–14 days (Hill et al 
2005a). The ﬁ  ndings from the initial pilot study all held up 
during the follow-up study, with the addition of quality-of-
life measurements being signiﬁ  cantly improved. It was also 
shown through this study that long-term eculizumab therapy 
is safe and well tolerated. In a study of two patients treated 
with eculizumab, intravascular hemolysis decreased, and 
symptoms associated with smooth muscle dystonia, such as 
abdominal pain, dysphagia, and erectile dysfunction, were 
also signiﬁ  cantly reduced (Hill et al 2005b).
All of this work provided the impetus for a future study 
involving larger numbers of patients in a double-blind, 
randomized, placebo-controlled phase III trial, termed the 
Transfusion Reduction Efﬁ  cacy and Safety Clinical Investi-
gation, a Randomized, Multicenter, Double-Blind, Placebo-
Controlled, Using Eculizumab in Paroxysmal Nocturnal 
Hemoglobinuria (TRIUMPH) study (Hillmen et al 2006). 
Eighty-seven patients were given either 600 mg eculizumab 
or placebo on a weekly basis for 4 weeks, then a 900 mg 
dose one week later, then 900 mg every other week up to 
26 weeks. The primary end points were the hemoglobin level 
and how many units of blood the patients needed during 
Table 1 Summary of anticomplement therapy used in clinical trials
Clinical situation  Principle of anticomplement therapy  Treatment
Paroxysmal nocturnal hemoglobinuria C5 inhibition Eculizumab (monoclonal antibody)
Paroxysmal nocturnal hemoglobinuria Replacement of deﬁ  cient complement 
inhibitor molcule
Recombinant soluble CD59
Glomerulonephritis C5 inhibition Eculizumab
AMI treated with thrombolysis Augmentation of complement inhibitory 
molecules
C1 inhibitor
AMI treated with thrombolysis C5 inhibition Pexelizumab (monoclonal antibody)
AMI treated with angioplasty C5 inhibition Pexelizumab (monoclonal antibody)
AMI treated with CABG surgery Augmentation of complement inhibitory 
molecules
C1 inhibitor
Cardiac surgery requiring CPB Augmentation of complement inhibitory 
molecules
TP10 (recombinant soluble complement receptor 1)
Cardiac surgery requiring CPB Inhibition of the complement system at 
many levels
Heparin
Cardiac surgery requiring CPB C5 inhibition Pexelizumab (monoclonal antibody)
Abbreviations: CABG, coronary artery bypass graft;   AMI, acute myocardial infarction; CPB, cardiopulmonary bypass; CD, cluster of differentiation.Biologics: Targets & Therapy 2008:2(4) 676
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the period of time of the study. Hemoglobin stabilization 
without transfusion occurred in 21 of 43 patients in the 
eculizumab group, while it occurred in 0 of 44 patients 
in the placebo group. A median of 10 units of blood were 
given to the placebo group during the study period, while the 
group receiving eculizumab required 0 units. In addition, the 
eculizumab group had a signiﬁ  cant decrease in LDH levels 
as well as a signiﬁ  cant increase in quality of life.
In a multinational open-label extension study of the TRI-
UMPH study using 195 patients, the same authors studied the 
effect of eculizumab on the occurrence of thromboembolism 
(TE) (Hillmen et al 2007). Prior to treatment, the TE event 
rate was 7.37/100 patient-years, whereas with treatment, the 
rate was 1.07/100 patient-years. It was thus concluded that 
treatment with eculizumab in PNH signiﬁ  cantly reduces the 
occurrence of TE.
Another possible option for the treatment of PNH is 
recombinant soluble CD59, since this is one of the critical 
membrane-bound proteins deﬁ  cient in PNH. In vitro studies 
with human PNH erythrocytes showed that recombinant 
soluble CD59 was able to bind to the surface of RBCs at 
levels sufﬁ  cient to inhibit complement-mediated hemolysis 
(Hill et al 2006). In an in vivo experiment, the RBCs of mice 
given recombinant soluble CD59 were partially protected 
from complement-mediated destruction. In a similar experi-
ment, a single-chain antibody variable region fragment tar-
geted against TER-119, a mouse RBC antigen, was attached 
to human DAF (Spitzer et al 2004). This recombinant protein 
was able to bind to mouse RBCs in vivo and protect them 
from complement-mediated destruction.
Glomerulonephritis
Overview and pathophysiology
The basic pathophysiology of glomerulonephritis is 
inflammation of the glomerulus, and the main clinical 
features of the various glomerulonephritides include 
proteinuria, hematuria, and decreased glomerular function 
(Javaid and Quigg 2005). End-stage renal disease can 
be the eventual outcome of glomerulonephritis, which 
leaves patients dependent on chronic dialysis and/or renal 
transplantation.
The complement system can play a signiﬁ  cant role in the 
inﬂ  ammation of glomerulonephritis. For example, greater 
than 80% of patients with Type II membranoproliferative 
glomerulonephritis (MPGN) are positive for serum 
C3-nephritic factor, an antibody against C3bBb which 
inhibits the dissociation of Bb from C3b (Daha et al 1976; 
Schwertz et al 2001). In patients with IgM nephropathy, 
serum C3 levels are directly correlated with proteinuria and 
progression of the disease (Myllymäki et al 2006).
The important role of the complement system in the 
development of different glomerular diseases has been shown 
in several animal models. Mice deﬁ  cient in FH develop 
Type II MPGN with deposition of C3 in the capillary walls 
(Pickering et al 2002). Of interest, mice deﬁ  cient in FH and 
C5 developed less severe disease than those only deﬁ  cient 
in FH (Pickering et al 2006).
Mice deficient in either DAF or DAF and CD59 
had an increased incidence of immune-complex-
mediated glomerulonephritis with increased glomerular 
deposition of C3 (Bao et al 2007). In a mouse model 
of immune-complex-mediated glomerulonephritis, 
CD59-deficient mice had more proteinuria (Turnberg 
et al 2003). Similarly, DAF-deficient mice and DAF- 
and CD59-combined knockout mice had much worse 
albuminuria in a model of nephrotoxic serum-induced 
nephritis (Lin et al 2004).
In another mouse model of progressive glomerlonephritis, 
C5a receptor (C5aR)-deﬁ  cient mice showed less interstitial 
damage than control mice (Welch et al 2002). Similarly, 
in a mouse model of lupus nephritis, a synthetic anti-C5a 
receptor molecule (a cyclic hexapeptide) led to less decline 
in renal function, as well as decreased inﬁ  ltration of kidneys 
by neutrophils and macrophages (Bao et al 2005).
Despite the etiologic role of the complement system 
in the pathogenesis of the majority of the glomerulone-
phritides, in some cases, a functional complement system 
might play a protective role against the development of 
glomerulonephritis. For example, factor D-deficient mice, 
which lack the alternative complement system, developed 
immune-complex glomerulonephritis (specifically 
Type II rapidly progressive glomerulonephritis) and 
showed mesangial deposition of IgM (Abrera-Abeleda 
et al 2007). Complement activity is necessary for the 
clearance of immune complexes from the body, and 
lack of this clearance activity due to a deficiency in 
complement activity might contribute to the development 
of glomerulonephritis. Another example of complement’s 
protective role in glomerulonephritis is that deficiencies 
in C1q, C2, or C4 predispose humans to the development 
of systemic lupus erythematosus (SLE) and lupus 
nephritis (Mitchell et al 2002). Presence of anti-C1q 
antibodies, resulting in the lack of a functional classical 
complement pathway, predicts with relatively high 
sensitivity and specificity the presence of active lupus 
nephritis (Moroni et al 2001; Trendelenburg et al 2006). Biologics: Targets & Therapy 2008:2(4) 677
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Anti-C1q antibodies are present in 30%–40% of patients 
with SLE (Seelen et al 2003).
One might conclude based on these various, then, that the 
early components of the complement system are probably 
necessary for normal homeostasis of the immune system 
and that their absence may predispose to the development of 
immune-complex disease. Thus, targeting later components 
of the complement system for anticomplement therapy in 
glomerulonephritis may be the best option (Berger and 
Daha 2007).
Therapy
The clinical trials of anticomplement agents in patients with 
kidney disease have been much more limited than those 
in PNH patients. Nonetheless, many in vitro experiments 
and animal studies have been conducted in various types 
of glomerulonephritis. Couser et al studied complement 
inhibition in three different animal models of complement-
mediated glomerulonephritis (Couser et al 1995). In these 
models, administration of sCR1 was able to reduce the 
morphologic and functional characteristics of renal disease, 
as measured by mesangiolysis, glomerular inﬁ  ltration by 
platelets and macrophages, and proteinuria.
In a mouse model of immune-complex-mediated 
glomerulonephritis, a monoclonal antibody against C5, 
BB5.1, was able to lessen renal disease and prolong survival 
(Wang et al 1996). The same antibody was also able to 
reduce proteinuria and renal damage in mice subjected to 
human antidouble-stranded DNA (Ravirajan et al 2004). 
In a mouse model of antimyeloperoxidase IgG-induced 
glomerulonephritis, administration of anti-C5 antibody 
(BB5.1) thwarted the development of glomerular disease, 
as shown by decreased hematuria, pyuria, albuminuria, and 
glomerular neutrophil inﬁ  ltration (Huugen et al 2007).
In a multicenter, randomized, placebo-controlled phase II 
trial conducted in the US on 122 patients with idiopathic 
membranous nephropathy, treatment with eculizumab did not 
decrease urinary protein excretion, the primary outcome goal 
of the study (Appel et al 2002). However, there was some 
beneﬁ  t with eculizumab in the open-label extension of the 
study. Currently, there is an ongoing trial with eculizumab 
in patients with membranous nephropathy; the results of this 
trial are still pending (Berger et al 2005; Javaid and Quigg 
2005; Brown et al 2007).
Coronary heart disease
Coronary artery disease (CAD) is one of the most common 
causes of morbidity and mortality in the United States and 
the world at large. A signiﬁ  cant amount of work has been 
done to better understand the role of the complement system 
in the pathology and pathophysiology of atherosclerosis 
and myocardial infarction (MI). This work has culminated 
in several clinical trials which have tested anticomplement 
therapy in the setting of acute myocardial infarction (AMI) 
and cardiac surgery.
Stable coronary artery disease
Overview and pathophysiology
It has long been known that the complement system is 
involved in the development of CAD. For example, even in the 
late 1970’s and throughout the 1980’s, it was repeatedly shown 
that C3 is present in atherosclerotic plaques (Hollander et al 
1979; Hansson et al 1984; Vlaicu et al 1985). Interestingly, 
complement regulatory proteins, including CR1, complement 
receptor 3, DAF, and CD59 are also present in atherosclerotic 
plaques, thus demonstrating activity and regulation of the 
complement system in atherosclerotic plaques (Seifert and 
Hansson 1989a, 1989b; Seifert et al 1992).
More recently, it was shown that C3 levels may be a good 
marker of insulin resistance, a risk factor for the development 
of diabetes mellitus (DM), and CAD (Muscari et al 2000). 
The level of C3 was a better predictor of blood pressure and 
glucose levels than the level of insulin itself. C3 levels also 
have an independent, signiﬁ  cant correlation with ﬁ  brinogen 
levels, body mass indices, platelet counts (important for the 
development of thrombi), insulin levels, triglyceride (TG) 
levels, and levels of low-density lipoprotein cholesterol 
(Capuano et al 2006).
To our knowledge, no clinical trials using anticomplement 
therapies have been conducted in patients with stable CAD. 
However, we describe this work because it is relevant to 
potential clinical studies that could be done in patients 
with CAD.
Acute myocardial infarction
Overview and pathophysiology
Involvement of the complement system in AMI has 
been shown since the 1970’s. It was ﬁ  rst observed that 
administration of CVF 30 min prior to occlusion of the left 
anterior descending coronary artery in dogs reduced necrosis 
and neutrophil inﬁ  ltration into the myocardium (Maroko 
et al 1978). The complement proteins C3, C4, and C5 were 
deposited on infarcted tissue in a baboon model of AMI, 
and Laine et al showed that there was extensive deposition 
of iC3b in ruptured plaques, as compared to nonruptured 
plaques, from human coronary arteries in patients who had Biologics: Targets & Therapy 2008:2(4) 678
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died from AMI (Pinckard et al 1980; McManus et al 1983; 
Laine et al 2002).
Patients with MI have increased post-infarction plasma 
levels of C5b-9 (Langlois and Gawryl 1988). Actually, 
levels of C3, C8, C9, and FB were all signiﬁ  cantly increased 
in patients 6 and 12 hours after admission for MI (Halas 
et al 2005). C5b-9 was also found to be present in higher 
quantities in pathologic specimens of atherosclerotic plaques 
from patients with acute coronary syndrome (ACS) as 
compared to those with stable angina (Meuwissen et al 2006). 
Interestingly, the presence of C5b-9 in necrotic tissue was 
associated with the loss of CD59 in postmortem studies on 
patients who died from MI (Väkevä et al 1992).
Recently, several complement proteins have been studied 
as predictive markers in CAD leading to MI. For example, 
there was a substantial correlation between C3 levels and 
several cardiovascular risk factors, such as blood pressure, 
body mass index, and serum lipid levels (Engström et al 
2007). C3 levels were shown to be a strong predictor of MI, 
especially in men, and C3a levels were elevated in patients 
with unstable angina as compared to those with stable angina 
(Muscari et al 1995; Kostner et al 2006). Finally, C3 and 
C4 levels in patients admitted for AMI were signiﬁ  cantly 
higher than in patients with stable angina or healthy controls, 
and the serum C3/C4 ratio could possibly be used as a 
marker of subsequent cardiovascular events after a previous 
manifestation of ACS (Iltumur et al 2005; Palikhe et al 
2007). Additionally, elevated C5a levels were shown to be 
associated with an increased risk of MI, PCIs, coronary artery 
bypass graft (CABG) surgery, carotid revascularization, 
stroke, or death in patients with advanced atherosclerosis 
(Speidl et al 2005).
C-reactive protein (CRP) interacts with the complement 
system. It was shown that CRP binds to damaged cardiomyocytes 
and activates the complement system (Kaplan and Volanakis 
1974; Siegel et al 1974; Volanakis and Kaplan 1974; Volanakis 
1982; Jiang et al 1992). The level of deposited CRP correlated 
with the extent of activation of the complement system in 
infarcted myocardial tissue as determined by measuring levels 
of complement proteins, CRP, and CRP-complement protein 
complexes (Nijmeijer et al 2003). In a rat model of MI, injection 
of human CRP increased the size of infarcted myocardial 
tissue. This effect of CRP was blocked by CVF-induced 
complement depletion even two hours after induction of MI 
(Griselli et al 1999).
The mainstay of treatment for MI is early revascularization 
through thrombolytic therapy, percutaneous coronary inter-
vention (PCI), or CABG surgery. However, revascularization 
carries with it the risk of ischemia-reperfusion injury, in which 
the complement system is activated. Reperfusion has been 
known to cause arrhythmias, microvascular dysfunction, and 
even cell death (Verma et al 2002). Reperfusion can also cause 
a condition known as myocardial stunning, which refers to 
diminished contractility of ischemic but still viable myocardium 
after full revascularization (Braunwald and Kloner 1982). The 
complement system has been shown to be involved in the acute 
inﬂ  ammatory response associated with ischemia-reperfusion 
injury (Yasuda et al 1990; Eltzschig and Collard 2004). Activation 
of the complement system increases vascular permeability, 
activates endothelial and inﬂ  ammatory cells, coagulates blood, 
and causes cell lysis.
Therapy
Several anticomplement therapies have been tried in different 
animal models of MI and ischemia-reperfusion, as well as in 
human clinical trials. One of the ﬁ  rst anticomplement reagents 
used was the soluble form of complement receptor 1 (sCR1), 
a recombinant protein that comprises the extracellular part 
of the complement regulatory protein CR1. In an isolated 
rat model of ischemia-reperfusion injury, sCR1 was able to 
prevent post-ischemic myocardial contractile dysfunction 
and enhance coronary blood ﬂ  ow (Shandelya et al 1993). 
sCR1 modiﬁ  ed with the addition of a myristoylated peptide 
sequence, creating a molecule known as Mirococept and 
giving sCR1 the ability to bind to cell membranes, decreased 
infarct size, reduced serum troponin I, and resulted in a lower 
amount of complement deposition and myocardial apoptosis 
in a pig model of AMI (Banz et al 2007).
C1-INH has also been used with some success in different 
models of MI and ischemia-reperfusion. In a cat model of 
ischemia-reperfusion, C1-INH given just before reperfusion 
reduced infarct size by 65% (Buerke et al 1995). In a rat 
model of MI, C1-INH suppressed C3 mRNA expression 
and protein synthesis, while in cultured rat cardiomyocytes, 
C1-INH blocked deposition of C3 (Fu et al 2006b). In 
the same model of MI in rats, C1-INH protected against 
cardiomyocyte apoptosis, improved cardiac function, reduced 
infarct size, and decreased inﬁ  ltration by neutrophils (Fu 
et al 2006a).
Treatment with C1-INH has also been studied in patients 
with MI. In one study, 22 patients received a loading dose 
of C1-INH followed by a continuous 48-hour infusion at 
least 6 hours after the onset of symptoms (de Zwaan et al 
2002). In this small study, a C1-INH dose-dependent reduc-
tion in activation fragments of C4 was shown. In 13 of the 
16 patients who received thrombolytic therapy and C1-INH, Biologics: Targets & Therapy 2008:2(4) 679
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the values of troponin T and creatine kinase-MB (CK-MB) 
were reduced by 36% and 57%, respectively, as compared 
to 18 control patients who had AMI and did not receive 
C1-INH therapy.
The other component of the complement cascade that has 
been the target of anticomplement therapy in MI is C5. In 
a dog model of cardiac ischemia induced by ligation of the 
left circumﬂ  ex artery, cardiac lymph obtained from the dogs 
several hours after reperfusion was able to activate neutro-
phils (Dreyer et al 1992). However, this effect was completely 
abolished when anti-C5a was added to the cardiac lymph. 
It was also shown that the monocyte chemotactic activity 
of cardiac lymph in the ﬁ  rst few hours after reperfusion is 
almost completely due to C5a (Birdsall et al 1997). More 
directly, in a porcine model of ischemia-reperfusion, a 
recombinant human C5 antagonist, CGS 32359, was able to 
inhibit neutrophil activation and reduce infarct size (Riley 
et al 2000). Finally, in a rat model of ischemia-reperfusion, a 
monoclonal antibody against C5 reduced apoptosis, necrosis, 
and neutrophil inﬁ  ltration (Vakeva et al 1998).
A large randomized, placebo-controlled phase II study 
of 960 patients, the COMplement inhibition in Myocardial 
infarction treated with Angioplasty (COMMA) trial, 
investigated the effect of anti-C5 therapy in AMI (Granger 
et al 2003). In this study, the anti-C5 agent pexelizumab 
(Alexion Pharmaceuticals, Cheshire, Connecticut, USA) 
was used. Patients with AMI who underwent primary 
PCI therapy were randomized to placebo, pexelizumab 
bolus given just before revascularization, and pexelizumab 
bolus plus subsequent infusion for 20 hours. There was no 
difference between the groups with respect to infarct size 
as determined by CK-MB area under the curve (AUC), but 
there was a signiﬁ  cant beneﬁ  t in 90-day mortality rate for 
the bolus plus infusion group (1.8%) as compared to the 
placebo group (5.9%).
In a substudy of the COMMA trial, there was a sig-
niﬁ  cant difference in the hemodynamic status of the groups 
treated with pexelizumab versus placebo after correcting for 
age, race, and MI location (Armstrong et al 2006). It was 
shown that this improved hemodynamic status was not due 
to infarct size, degree of ST-segment elevation, or extent of 
reperfusion. In another substudy of the COMMA trial, it was 
shown that higher CRP and interleukin-6 (IL-6) levels at base-
line, 24 hours, and 72 hours were associated with increased 
death, and that elevated CRP, IL-6, and tumor necrosis 
factor-α levels were associated with more cardiogenic shock 
or death within 90 days of treatment (Théroux et al 2005). 
Despite similar serum levels of CRP and IL-6 at baseline, 
the pexelizumab-treated groups had signiﬁ  cantly lower CRP 
and IL-6 levels at 24 hours, but by 72 hours, the values were 
similar between different groups.
The COMMA trial was the ﬁ  rst part of a two-part phase II 
clinical trial called the Complement And ReDuction of INfarct 
size after Angioplasty or Lytics (CARDINAL) program. The 
results of the second part of the CARDINAL study, known as 
the COMPlement inhibition in myocardial infarction treated 
with thromboLYtics (COMPLY) trial, were also reported in 
2003 (Mahaffey et al 2003). In this study, 943 patients who 
underwent ﬁ  brinolysis for ST-segment elevation MI (STEMI) 
were randomized similarly to the way patients were random-
ized in the COMMA trial. It was shown that pexelizumab 
lowered complement activity but had no effect on infarct size 
as measured by CK-MB AUC or on adverse clinical outcomes 
in the 90 days following treatment.
The follow-up to the CARDINAL program was a large, 
prospective, multicenter, randomized, double-blind, placebo-
controlled phase III trial in which 5745 patients who had a 
STEMI treated with PCI were randomized to either placebo 
or treatment with pexelizumab as a bolus just before PCI and 
then as a 24-hour infusion after revascularization therapy 
(APEX AMI Investigators et al 2007). This trial showed 
no difference in 30-day all-cause mortality or in the 90-day 
composite of death, cardiogenic shock, or congestive heart 
failure.
Coronary artery bypass graft surgery, 
ischemia-reperfusion injury, 
and cardiopulmonary bypass
After revascularization with emergent CABG surgery in the 
setting of AMI, reperfusion can activate the complement sys-
tem, similar to reperfusion with thrombolysis or angioplasty. 
Also, in cardiac surgery, use of cardiopulmonary bypass 
(CPB) exposes blood to nonself material in extracorporeal 
circuits, which in turn activate the alternative complement 
system. Thus, inhibition of complement activity may be ben-
eﬁ  cial in decreasing inﬂ  ammation and tissue injury resulting 
from CABG surgery through two mechanisms, prevention 
of revascularization injury and reduced activation of the 
complement system associated with exposure of blood to 
extracorporeal circuits.
The effect of C1-INH was studied in 67 patients 
who underwent emergency CABG surgery for STEMI 
(Thielmann et al 2006). In this study, a bolus of C1-INH was 
given during, and another bolus given 6 hours after, surgery. 
It was shown that if C1-INH was given within 6 hours of 
the onset of symptoms, troponin I levels were reduced, but Biologics: Targets & Therapy 2008:2(4) 680
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administration of C1-INH between 6 and 24 hours after the 
onset of symptoms failed to decrease troponin I levels. There 
was no difference between patients who received C1-INH 
and those who did not with respect to the length of hospital or 
intensive care unit (ICU) stays, post-operative complications, 
or in-hospital mortality, regardless of the initiation time of 
C1-INH infusion.
In another randomized, double-blind, placebo-controlled 
study, 80 patients with STEMI who underwent emergent 
CABG surgery were enrolled, with half receiving C1-INH 
and the other half receiving only a saline solution (Fattouch 
et al 2007). Patients received a bolus of C1-INH 10 min 
before reperfusion and then an intravenous infusion for 
3 hours after surgery. Those receiving C1-INH showed a 
beneﬁ  t in the amount of inotrope drugs required, intubation 
time, length of ICU stay, and various measures of cardiac 
function, such as mean arterial pressure, cardiac index, and 
stroke volume. The levels of troponin I after reperfusion were 
signiﬁ  cantly lower in the C1-INH group as compared to the 
placebo group. However, the rate of early mortality was not 
signiﬁ  cantly different between the two groups.
In one study of 564 patients, TP10 (a recombinant sCR1) 
or placebo was given to high-risk patients undergoing cardiac 
surgery requiring CPB (Lazar et al 2004). TP10 inhibited the 
complement system after 10–15 min of CPB, an inhibition 
which persisted until post-operative day (POD) 3. The primary 
endpoint in this study was death, MI, prolonged intra-aortic 
balloon pump support, and prolonged intubation. The TP10 
group showed a lower primary endpoint event rate by 30% 
only in male patients. In a follow-up study of 297 female 
patients randomized to treatment with TP10 or placebo, it 
was shown that TP10 suppressed complement activation 
but did not reduce the incidence of death or MI by 28 days 
after surgery (Lazar et al 2007). A possible reason for this 
lack of difference is that the number of adverse events in the 
control arm of this trial was quite low to begin with, at 17%. 
Therefore, it became difﬁ  cult to prove any statistical differ-
ence with only 297 patients. Thus, the study size combined 
with the low event rate in the placebo group together made it 
difﬁ  cult to show any beneﬁ  cial effect of TP10.
Heparin, as mentioned earlier, has long been known 
to possess anticomplement activity. In a pig model of 
ischemia-reperfusion, 40 pigs were studied: 10 pigs 
received sCR1, 10 underwent surgery with heparin-bonded 
CPB (HB-CPB) circuits, 10 received sCR1 and underwent 
surgery with HB-CPB circuits, and 10 neither received 
sCR1 nor underwent surgery with HB-CPB circuits (Lazar 
et al 1999). As expected, sCR1 combined with the use of 
HB-CPB circuits led to less myocardial tissue acidosis, 
better recovery of wall motion, less pulmonary edema, and 
smaller infarct size.
In a human trial, the effect of heparin on complement 
activation was studied in 151 patients undergoing cardiac 
surgery. Heparin coating of CBP circuits reduced complement 
activation, especially C5b-9 formation, but did not reduce the 
release of the neutrophil granule enzymes myeloperoxidase 
and lactoferrin (Fosse et al 1997).
Pexelizumab has also been studied in patients undergoing 
cardiac surgery requiring CPB. One of the ﬁ  rst studies 
conducted was a prospective, open-label, randomized phase I 
study in 17 patients who underwent primary, nonemergent 
CABG surgery with CPB. In the ﬁ  rst phase of the study, 
patients were randomized to receive escalating doses 
of h5G1.1-scFv (not yet known as pexelizumab) (Fitch 
et al 1999). In another part of the study, 18 patients were 
randomized into 3 groups and received placebo or one of two 
different doses of h5G1.1-scFv. It was shown that leukocyte 
activation, determined by expression of CD11b, was reduced 
in patients receiving the higher doses of h5G1.1-scFv. In those 
patients receiving the highest dose of h5G1.1-scFv (2 mg/kg), 
a 40% reduction in CK-MB was observed. In addition, in 
patients treated with the highest dose of h5G1.1-scFv, there 
was an 80% reduction in new cognitive deﬁ  cits as determined 
by sequential mini-mental status exams.
In a follow-up to this study, a randomized, double-blind, 
placebo-controlled multicenter phase II trial in patients who 
underwent nonemergent CABG surgery with or without 
concomitant valve surgery, participants were randomized 
into three groups, those receiving placebo, those receiving a 
pexelizumab bolus, and those receiving a pexelizumab bolus 
and subsequent infusion (Shernan et al 2004). It was shown 
that giving pexelizumab as a bolus plus infusion reduced 
the composite of death or MI in patients undergoing CABG 
surgery only without valve surgery on POD 4 and POD 30. 
There was, however, no difference in the primary endpoint, 
namely the composite of death, new MI, left ventricular 
dysfunction, or new neurological events, between the two 
groups overall.
This phase II trial was further analyzed from the 
neurological perspective in a follow-up substudy (Mathew 
et al 2004). Neurological and neurocognitive functions were 
assessed on POD 4 and POD 30 in patients enrolled in the 
substudy. Pexelizumab had no effect on overall cognition 
on either day. The only difference was in visuo-spatial 
function, which was signiﬁ  cantly better in the treated group 
as compared to the placebo group on POD 4 and POD 30.Biologics: Targets & Therapy 2008:2(4) 681
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This phase II trial was followed up with a larger phase III, 
randomized, double-blind, placebo-controlled, multicenter 
study of 3099 patients undergoing nonemergent CABG 
surgery with or without valve surgery (Verrier et al 2004). 
In this study, termed the Pexelizumab for Reduction in 
Infarction and MOrtality in Coronary Artery Bypass Graft 
surgery (PRIMO-CABG) trial, patients were randomized 
into two groups, one receiving an intravenous bolus of 
pexelizumab plus a subsequent 24-hour infusion and the other 
receiving placebo. The primary endpoint in this trial was the 
composite of death or MI within 30 days of surgery. This 
large, extensive study did not show any signiﬁ  cant difference 
between the two groups with regard to the incidence of death 
or MI at 30 days, with the event rate being 9.8% (134/1373) 
in patients who received pexelizumab and 11.8% (161/1359) 
in patients who received placebo (p = 0.07).
In a substudy of the PRIMO-CABG trial, it was shown 
that pexelizumab reduced the incidence of death or MI by 
POD 30 by 28% in patients with two or more risk factors, 
including DM, prior CABG surgery, urgent intervention, 
female sex, history of a neurological event, CHF, two or 
more previous MIs, or a recent MI (Haverich et al 2006). In 
separate follow-up analysis, a subgroup of patients with aortic 
cross-clamp times 90 min showed reduced perioperative 
myocardial injury (Smith et al 2006). Of this speciﬁ  c subset 
of patients, those with two or more serious cardiovascular 
risk factors had a reduced incidence of death or MI through 
POD 30 and a signiﬁ  cantly reduced incidence of mortality 
180 days after surgery.
In one final substudy analysis of patients in the 
PRIMO-CABG trial, pexelizumab reduced mortality at 
180 days in patients who underwent aortic valve replacement 
(AVR) at the time of CABG surgery (Carrier et al 2006). 
However, both mortality and the incidence of MI at 30 days 
were not signiﬁ  cantly different between those who had an 
AVR with their CABG surgery and those who did not.
In a broad meta-analysis of the four large trials with 
pexelizumab described above (COMMA, COMPLY, 
Phase II CABG study, and PRIMO-CABG), using data from 
5916 patients who either had an AMI treated with PCI or 
thrombolytic therapy or who underwent CABG surgery, it 
was shown that pexelizumab reduced 30-day mortality when 
given as a bolus followed by subsequent infusion (Mahaffey 
et al 2006).
The angioplasty, thrombolytic, and CABG surgery 
trials involving anticomplement therapy did not provide 
as much beneﬁ  t to patients as had been hoped for. We can 
only speculate about why the in vitro and animal studies 
did not translate to successful therapeutic results in human 
trials; however, advances in the complement science and 
in understanding of thrombotic disorders will provide the 
real answers.
Future directions
In addition to the clinical applications described in the 
previous section, there are two other main clinical conditions 
with potential therapeutic roles for complement regulatory 
proteins.
Sepsis
There are several studies reporting an increase in complement 
activation products (C5a, C3a, C5b-9) in animal models 
of sepsis, as well as in patients with sepsis and multiorgan 
system failure (Ward 2008). For example, in the setting of 
experimental sepsis in mice or rats induced by cecal ligation 
and puncture, there is an upregulation of C5a receptor 
(C5aR) in solid organs and on the surface of neutrophils 
(Riedemann et al 2002; Ward 2008). Despite an increase in 
the concentration of C5a, the normal functions of neutrophils, 
including chemotaxis, phagocytosis, and oxidative burst, 
are impaired during sepsis (Huber-Lang et al 2002b). These 
abnormalities in neutrophil function are probably due to a 
paralysis of C5a signaling (Ward 2008). Using anti-C5a 
antibody or anti-C5aR cyclic peptide can reverse neutrophil 
paralysis and, more importantly, can increase survival in 
animals with severe sepsis (Huber-Lang et al 2001, 2002a). 
To date, no trials using anti-C5a antibody or anti-C5aR agents 
have been performed in patients with sepsis.
Age-related macular degeneration
Age-related macular degeneration (AMD) is a leading cause of 
blindness among older individuals in developed countries. In 
1998, a genome-wide screening study in a family with AMD 
identiﬁ  ed the long arm of chromosome 1 (1q25–q31) as the 
locus for the responsible gene (Klein et al 1998). In 2005, three 
independent studies using different methods identiﬁ  ed an asso-
ciation between a polymorphism in factor H (Tyr402His) and 
AMD in the general population (Edwards et al 2005; Haines 
et al 2005; Klein et al 2005). Later on, associations between 
AMD and additional polymorphisms in the factor H gene, as 
well as polymorphisms in other complement proteins, were 
detected (Gold et al 2006; Hughes et al 2006; Li et al 2006; 
Maller et al 2006; Dinu et al 2007). Functional and anatomical 
studies conducted on factor H-deficient mice revealed a 
signiﬁ  cant reduction in visual acuity and abnormalities in 
electroretinography of factor H-deﬁ  cient mice as compared to Biologics: Targets & Therapy 2008:2(4) 682
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control mice (Coffey et al 2007). These functional abnormalities 
were associated with complement deposition and altered retinal 
structure. Studies using factor H puriﬁ  ed from serum and 
recombinant factor H showed decreased binding of the 402His 
variant of factor H to CRP and heparin as compared to the 
wild-type 402Tyr variant (Clark et al 2006; Laine et al 2007). 
Despite the presence of strong data linking polymorphisms in 
factor H to retinal damage in AMD, further animal and human 
studies are required before this information may be applied to 
clinical use.
Conclusion
The ﬁ  eld of anticomplement therapy is a rapidly-evolving 
one and has much potential for future beneﬁ  t in clinical 
medicine. It will arguably have the most impact in the 
treatment of PNH, for which anticomplement therapy has 
been shown to be a highly effective treatment. As for the 
use of anticomplement therapy in the treatment of CAD 
and its complications, initial studies appeared promising, 
but larger, more extensive studies turned out to be more 
disappointing than had been desired. However, since the 
complement system is a complex, multifaceted system, there 
are potentially many more therapeutic targets that may be 
exploited in the future for the treatment of CAD, glomeru-
lonephritis, sepsis, AMD, and many other diseases.
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